Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABEONA THERAPEUTICS INC.ABEO · Entity 5808 | Director | June 17, 2020 | June 19, 2020 |
| Immunovant, Inc.IMVT · Entity 3632 | Director | April 01, 2025 | April 03, 2025 |
| OCULAR THERAPEUTIX, INCOCUL · Entity 273 | Interim CFO | April 06, 2017 | April 12, 2017 |
| REGENXBIO Inc.RGNX · Entity 2211 | Director | May 29, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABEONA THERAPEUTICS INC.
Report date June 17, 2020 · Filed June 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,954 |
Reported balance
After 2020-06-17 transaction · row 1
1 source rowRow 1 · 2020-06-17 · Grant · Acquired 37,954 · Balance 37,954 F1: All of the restricted stock will vest on December 17, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.03 · Expires 2030-06-17 | Direct | 45,566 |
Reported balance
After 2020-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-06-17 · Grant · Acquired 45,566 · Balance 45,566 F2: All of the stock options will vest on December 17, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the restricted stock will vest on December 17, 2020.
F2: All of the stock options will vest on December 17, 2020.
Immunovant, Inc.
Report date April 01, 2025 · Filed April 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 137,251 |
Reported balance
After 2025-04-01 transaction · row 1
1 source rowRow 1 · 2025-04-01 · Grant · Acquired 16,188 · Balance 137,251 F1: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.20 · Expires 2035-04-01 | Direct | 7,600 |
Reported balance
After 2025-04-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-04-01 · Grant · Acquired 7,600 · Balance 7,600 F2: The shares underlying the options will vest on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.
F2: The shares underlying the options will vest on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date.
OCULAR THERAPEUTIX, INC
Report date April 06, 2017 · Filed April 12, 2017
This filing explicitly reported no securities owned.
REGENXBIO Inc.
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,861 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Grant · Acquired 9,807 · Balance 28,861 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2036-05-29 | Direct | 46,600 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Grant · Acquired 46,600 · Balance 46,600 F2: The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.
F2: The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dimension Therapeutics, Inc.
Report date November 07, 2017 · Filed November 07, 2017
Section 16 reporting ended · disclosed 2017-11-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.09 · Expires 2025-06-02 | Direct | 0 |
Reported balance
After 2017-11-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-11-07 · Disposition to issuer · Disposed 55,772 · Balance 0 F1: This stock option, which vests in equal monthly installments over 48 months beginning June 3, 2015, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger dated October 2, 2017 between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.08 · Expires 2026-05-18 | Direct | 0 |
Reported balance
After 2017-11-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-11-07 · Disposition to issuer · Disposed 32,069 · Balance 0 F2: These options were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2027-05-24 | Direct | 0 |
Reported balance
After 2017-11-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-11-07 · Disposition to issuer · Disposed 17,000 · Balance 0 F3: These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option, which vests in equal monthly installments over 48 months beginning June 3, 2015, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger dated October 2, 2017 between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx.
F2: These options were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
F3: These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2026 Filed Jun 2, 2026 21:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 46,600 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0001134365-26-000001 · primarydocument.xml · derivative · entry 2 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,600 Underlying: Common Stock · 46,600 shares Expires 2036-05-29 F2 · derivative.exercise_date: The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 21:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 9,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001134365-26-000001 · primarydocument.xml · nonDerivative · entry 1 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,861 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:32 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 39,815 | $0.00 Strike: $8.85 | $0.00 |
DisclosureSEC source: 0001562180-25-004350 · primarydocument.xml · derivative · entry 2 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,815 Underlying: Common Stock · 39,815 shares Expires 2035-05-30 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 30, 2025 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:32 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 7,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004350 · primarydocument.xml · nonDerivative · entry 1 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,054 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 1, 2026 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:39 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 7,600 | $0.00 Strike: $15.20 | $0.00 |
DisclosureSEC source: 0001764013-25-000041 · wk-form4_1743712786.xml · derivative · entry 2 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,600 Underlying: Common Stock · 7,600 shares Expires 2035-04-01 F2 · derivative.exercise_date: The shares underlying the options will vest on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:39 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 16,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-25-000041 · wk-form4_1743712786.xml · nonDerivative · entry 1 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,251 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:43 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 24,454 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001562180-24-004655 · primarydocument.xml · derivative · entry 2 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,454 Underlying: Common Stock · 24,454 shares Expires 2034-05-31 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 31, 2024 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:43 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 4,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-004655 · primarydocument.xml · nonDerivative · entry 1 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,286 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 1, 2025 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:48 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 4,690 | $0.00 Strike: $30.78 | $0.00 |
DisclosureSEC source: 0001764013-24-000063 · wk-form4_1712263688.xml · derivative · entry 2 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,690 Underlying: Common Stock · 4,690 shares Expires 2034-04-02 F2 · derivative.exercise_date: The shares underlying the options will vest on April 2, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:48 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 11,255 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-24-000063 · wk-form4_1712263688.xml · nonDerivative · entry 1 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,063 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 2, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:25 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 5,022 | $40.46 | $203,190.12 |
DisclosureSEC source: 0001764013-23-000153 · wk-form4_1701811523.xml · nonDerivative · entry 3 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,808 F1 · security: Represents the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan adopted on May 24, 2023, in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the above award of restricted stock covering shares of common stock and does not represent a discretionary sale by the reporting person. F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40.20 - $40.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:25 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 3,478 | $39.81 | $138,459.18 |
DisclosureSEC source: 0001764013-23-000153 · wk-form4_1701811523.xml · nonDerivative · entry 2 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,830 F1 · security: Represents the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan adopted on May 24, 2023, in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the above award of restricted stock covering shares of common stock and does not represent a discretionary sale by the reporting person. F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $39.20 - $40.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:25 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 4,200 | $38.79 | $162,918.00 |
DisclosureSEC source: 0001764013-23-000153 · wk-form4_1701811523.xml · nonDerivative · entry 1 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,308 F1 · security: Represents the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan adopted on May 24, 2023, in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the above award of restricted stock covering shares of common stock and does not represent a discretionary sale by the reporting person. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.20 - $39.19 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 21:12 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 17,892 | $0.00 Strike: $19.72 | $0.00 |
DisclosureSEC source: 0001562180-23-004892 · primarydocument.xml · derivative · entry 2 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,892 Underlying: Common Stock · 17,892 shares Expires 2033-06-02 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following June 2, 2023 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 21:12 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 3,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-004892 · primarydocument.xml · nonDerivative · entry 1 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,496 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 1, 2024 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 20:31 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 16,260 | $0.00 Strike: $14.70 | $0.00 |
DisclosureSEC source: 0001764013-23-000044 · wf-form4_168150426702734.xml · derivative · entry 2 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,260 Underlying: Common Stock · 16,260 shares Expires 2033-04-12 F3 · derivative.exercise_date: The shares underlying the options vest one year after the date of grant on April 12, 2024, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 20:31 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 12,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-23-000044 · wf-form4_168150426702734.xml · nonDerivative · entry 1 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,508 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest in their entirety one year after the date of grant on April 12, 2024, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:44 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 31,668 | $0.00 Strike: $4.99 | $0.00 |
DisclosureSEC source: 0001764013-22-000093 · wf-form4_166094182912795.xml · derivative · entry 2 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,668 Underlying: Common Stock · 31,668 shares Expires 2032-08-17 F3 · derivative.exercise_date: The shares underlying the options vest one year after the date of grant on August 17, 2023, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:44 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 21,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-22-000093 · wf-form4_166094182912795.xml · nonDerivative · entry 1 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,985 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest in their entirety one year after the date of grant on August 17, 2023, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 20:21 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 15,324 | $0.00 Strike: $22.84 | $0.00 |
DisclosureSEC source: 0001562180-22-004879 · primarydocument.xml · derivative · entry 2 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,324 Underlying: Common Stock · 15,324 shares Expires 2032-06-03 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following June 3, 2022 while the optionee provides continuous service to the Issuer. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 20:21 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 3,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-004879 · primarydocument.xml · nonDerivative · entry 1 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,010 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 1, 2023 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 22:03 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 71,492 | $0.00 Strike: $7.94 | $0.00 |
DisclosureSEC source: 0001764013-22-000019 · wf-form4_164202501508435.xml · derivative · entry 2 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,792 Underlying: Common Stock · 71,492 shares Expires 2032-01-10 F3 · derivative.exercise_date: Shares underlying the options vest over a period of two years, in a series of eight successive equal installments from the date of the award, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 22:03 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 21,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-22-000019 · wf-form4_164202501508435.xml · nonDerivative · entry 1 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,926 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest over a period of two years, in a series of eight successive equal installments from the date of the award, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 20:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $34.98 | $0.00 |
DisclosureSEC source: 0001562180-21-005879 · primarydocument.xml · derivative · entry 1 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-09-03 F1 · derivative.exercise_date: The option will vest in equal monthly installments over the 36 months following September 3, 2021, with immediate full vesting in the event of a change in control. Read SEC document |
| August 20, 2021 Filed Aug 20, 2021 22:14 UTC | Immunovant, Inc. IMVT · Entity 3632 | PurchaseCommon Stock | 7,000 | $7.65 | $53,550.00 |
DisclosureSEC source: 0001764013-21-000090 · wf-form4_162949763817516.xml · nonDerivative · entry 1 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,200 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.64 - $7.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 12:58 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 23,300 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001764013-21-000045 · wf-form4_161650431840974.xml · derivative · entry 2 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,300 Underlying: Common Stock · 23,300 shares Expires 2031-03-19 F3 · derivative.exercise_date: The shares underlying the options vest one year after the date of grant on March 19, 2022, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 12:58 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 15,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-21-000045 · wf-form4_161650431840974.xml · nonDerivative · entry 1 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,200 F1 · shares: Represents the number of shares underlying restricted stock unit awards ("RSUs") granted to the Reporting Person pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in their entirety one year after the date of grant on March 19, 2022, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. F2 · balance_after: 20,000 shares are the result of a pro rata distribution from Health Sciences Holdings, LLC, of which the Reporting Person was a member of Health Sciences Acquisition Corporation's board of directors. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:15 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 45,566 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0001493152-20-011509 · ownership.xml · derivative · entry 2 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,566 Underlying: Common Stock · 45,566 shares Expires 2030-06-17 F2 · derivative.exercise_date: All of the stock options will vest on December 17, 2020. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:15 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 37,954 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-011509 · ownership.xml · nonDerivative · entry 1 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,954 F1 · shares: All of the restricted stock will vest on December 17, 2020. Read SEC document |
| May 15, 2020 Filed May 18, 2020 12:52 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 37,000 | $0.00 Strike: $19.01 | $0.00 |
DisclosureSEC source: 0001209191-20-029944 · doc4.xml · derivative · entry 3 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires 2030-05-14 F2 · derivative.exercise_date: The shares underlying the option vest in eight equal quarterly installments measured from May 15, 2020, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| May 15, 2020 Filed May 18, 2020 12:52 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 24,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-029944 · doc4.xml · nonDerivative · entry 1 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,700 F1 · shares: Represents the number of shares underlying restricted stock units awards ("RSUs") pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in two equal annual installments on May 15, 2021 and May 15, 2022, subject to the Reporting Person's continued service to the Issuer as of each such date; provided that each director may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A regulation. F1 · price: Represents the number of shares underlying restricted stock units awards ("RSUs") pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in two equal annual installments on May 15, 2021 and May 15, 2022, subject to the Reporting Person's continued service to the Issuer as of each such date; provided that each director may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A regulation. Read SEC document |
| November 07, 2017 Filed Nov 7, 2017 22:09 UTC | Dimension Therapeutics, Inc. DMTX · Entity 172012 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,000 | Not disclosed Strike: $1.15 | Not disclosed |
DisclosureSEC source: 0001209191-17-059630 · doc4.xml · derivative · entry 3 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires 2027-05-24 F3 · price: These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. F3 · derivative.exercise_date: These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. Read SEC document |
| November 07, 2017 Filed Nov 7, 2017 22:09 UTC | Dimension Therapeutics, Inc. DMTX · Entity 172012 | Disposition to issuerStock Option (Right to Buy) · Derivative | 32,069 | Not disclosed Strike: $7.08 | Not disclosed |
DisclosureSEC source: 0001209191-17-059630 · doc4.xml · derivative · entry 2 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,069 shares Expires 2026-05-18 F2 · price: These options were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. F2 · derivative.exercise_date: These options were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. Read SEC document |
| November 07, 2017 Filed Nov 7, 2017 22:09 UTC | Dimension Therapeutics, Inc. DMTX · Entity 172012 | Disposition to issuerStock Option (Right to Buy) · Derivative | 55,772 | Not disclosed Strike: $4.09 | Not disclosed |
DisclosureSEC source: 0001209191-17-059630 · doc4.xml · derivative · entry 1 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,772 shares Expires 2025-06-02 F1 · price: This stock option, which vests in equal monthly installments over 48 months beginning June 3, 2015, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger dated October 2, 2017 between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx. F1 · derivative.exercise_date: This stock option, which vests in equal monthly installments over 48 months beginning June 3, 2015, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger dated October 2, 2017 between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx. Read SEC document |
| May 25, 2017 Filed May 26, 2017 20:47 UTC | Dimension Therapeutics, Inc. DMTX · Entity 172012 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001209191-17-035881 · doc4.xml · derivative · entry 1 MIGAUSKY GEORGE V · CIK 0001134365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2027-05-24 F1 · derivative.exercise_date: The options shall vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.